leon-nanodrugs secures funds in a series D financing

LEON announced today the closing of a Series D financing round. New lead investor LBBW Venture Capital closed the round together with new investors and existing shareholders like Albany Private Equity Holdings Pty Ltd., CD-Venture GmbH, Eckenstein-Geigy-Stiftung, Signet Healthcare Partners, TVM Life Science Innovation I L.P., and others.

 

READ MORE

 

 

 

LEON : Enabling Nano Now

About LEON

Based in Planegg/Munich, leon-nanodrugs GmbH is a pharmatech company specializing in the development and commercialization of equipment for the encapsulation of genetic material and other pharmaceutical active substances into nanoparticles, such as lipid nanoparticles (LNPs).

The company leverages its proprietary FR-JET®  technology to build innovative solutions. Its equipment portfolio includes NANOscreen® for formulation screening, NANOlab® for process development, as well as NANOme® and NANOus® for GMP manufacture. These systems are suitable for both individualized scales and commercial production, and the company further supports its clients by offering formulation and process development services.

LEON’s platform aims to empower pharmaceutical companies, small biotech, research institutes, and CDMOs to capitalize on advancements in advanced therapies.

For general information and enquiries please email info@leon-nanodrugs.com